article australian, page-10

So what 50 million gross sales for FY12?
= around maybe 10 million net profit to ACL with an average total market share of around 15% for the year if you use a 340m market

So roughly if we had 45% market share( Alot less than we should really end up with if you believe the FTC reports) then that would take us to 30 million PA, minus the 2 million API deduction fee= 28mil + the $$ improvements gained from increased yield - cost of running ACL = 30 mil net?. That could work out around what was originally forecast.

"Sales of fondaparinux by DRL in the US are in line with the Company’s expectations"

Maybe soon